NASDAQ:FCSC - Fibrocell Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.87 -0.28 (-8.89 %)
(As of 05/27/2018 05:39 AM ET)
Previous Close$2.87
Today's Range$2.72 - $5.17
52-Week Range$2.55 - $23.20
Volume6.80 million shs
Average Volume230,605 shs
Market Capitalization$16.28 million
P/E RatioN/A
Dividend YieldN/A
Beta0.45

About Fibrocell (NASDAQ:FCSC)

Fibrocell logoFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

Receive FCSC News and Ratings via Email

Sign-up to receive the latest news and ratings for FCSC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FCSC
CUSIPN/A
Phone484-713-6000

Debt

Debt-to-Equity RatioN/A
Current Ratio6.75
Quick Ratio6.75

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$350,000.00
Price / Sales46.49
Cash FlowN/A
Price / CashN/A
Book Value$1.10 per share
Price / Book2.61

Profitability

EPS (Most Recent Fiscal Year)($8.25)
Net Income$-16,240,000.00
Net MarginsN/A
Return on Equity-886.87%
Return on Assets-115.44%

Miscellaneous

Employees20
Outstanding Shares5,670,000

Fibrocell (NASDAQ:FCSC) Frequently Asked Questions

What is Fibrocell's stock symbol?

Fibrocell trades on the NASDAQ under the ticker symbol "FCSC."

When did Fibrocell's stock split? How did Fibrocell's stock split work?

Shares of Fibrocell reverse split on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of Fibrocell stock prior to the reverse split would have 20 shares after the split.

How were Fibrocell's earnings last quarter?

Fibrocell (NASDAQ:FCSC) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.30. View Fibrocell's Earnings History.

When is Fibrocell's next earnings date?

Fibrocell is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Fibrocell.

What price target have analysts set for FCSC?

3 brokers have issued 1-year price objectives for Fibrocell's shares. Their forecasts range from $30.00 to $35.00. On average, they expect Fibrocell's share price to reach $32.50 in the next year. View Analyst Ratings for Fibrocell.

Who are some of Fibrocell's key competitors?

Who are Fibrocell's key executives?

Fibrocell's management team includes the folowing people:
  • Mr. John Michael Maslowski, Pres, CEO, PFO, Principal Accounting Officer & Director (Age 43)
  • Mr. Robert G. Partridge, VP of Global Marketing, Communications and Investor Relations
  • Ms. Elizabeth A. Browning, Exec. VP of Marketing
  • Ms. Michele Mchugh-Mazzatta, VP of Sales
  • Dr. Pierre Compte, Managing Director of Switzerland

Has Fibrocell been receiving favorable news coverage?

Media coverage about FCSC stock has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fibrocell earned a media sentiment score of 0.14 on Accern's scale. They also gave news headlines about the company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Fibrocell's major shareholders?

Fibrocell's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (1.41%). Company insiders that own Fibrocell stock include David Pernock and Randal J Kirk. View Institutional Ownership Trends for Fibrocell.

Which major investors are buying Fibrocell stock?

FCSC stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P.. Company insiders that have bought Fibrocell stock in the last two years include David Pernock and Randal J Kirk. View Insider Buying and Selling for Fibrocell.

How do I buy shares of Fibrocell?

Shares of FCSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fibrocell's stock price today?

One share of FCSC stock can currently be purchased for approximately $2.87.

How big of a company is Fibrocell?

Fibrocell has a market capitalization of $16.28 million and generates $350,000.00 in revenue each year. The company earns $-16,240,000.00 in net income (profit) each year or ($8.25) on an earnings per share basis. Fibrocell employs 20 workers across the globe.

How can I contact Fibrocell?

Fibrocell's mailing address is 405 EAGLEVIEW BOULEVARD, EXTON PA, 19341. The company can be reached via phone at 484-713-6000 or via email at [email protected]


MarketBeat Community Rating for Fibrocell (FCSC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about Fibrocell and other stocks. Vote "Outperform" if you believe FCSC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FCSC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Fibrocell (NASDAQ:FCSC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Fibrocell in the last 12 months. Their average twelve-month price target is $32.50, suggesting that the stock has a possible upside of 1,032.40%. The high price target for FCSC is $35.00 and the low price target for FCSC is $30.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.50$32.50$25.00$27.6667
Price Target Upside: 1,032.40% upside5,503.45% upside646.27% upside83.22% upside

Fibrocell (NASDAQ:FCSC) Consensus Price Target History

Price Target History for Fibrocell (NASDAQ:FCSC)

Fibrocell (NASDAQ:FCSC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018HC WainwrightSet Price TargetBuy$30.00HighView Rating Details
4/2/2018Griffin SecuritiesReiterated RatingBuyLowView Rating Details
9/11/2017Canaccord GenuityReiterated RatingBuy$15.00 ➝ $35.00LowView Rating Details
3/7/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$10.00N/AView Rating Details
6/8/2016Roth CapitalReiterated RatingBuy$25.00N/AView Rating Details
6/8/2016WedbushReiterated RatingNeutral$7.50 ➝ $20.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Fibrocell (NASDAQ:FCSC) Earnings History and Estimates Chart

Earnings by Quarter for Fibrocell (NASDAQ:FCSC)

Fibrocell (NASDAQ:FCSC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.26)($0.26)($0.26)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.23)($0.23)($0.23)

Fibrocell (NASDAQ FCSC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.14)N/AView Earnings Details
5/10/2018Q1 2018($0.85)($0.55)ViewN/AView Earnings Details
3/19/2018Q4 2017($1.15)($3.25)ViewListenView Earnings Details
11/13/2017Q3 2017($2.05)($1.70)ViewN/AView Earnings Details
8/9/2017Q2 2017($1.55)($1.55)ViewListenView Earnings Details
5/10/2017Q1 2017($1.45)($2.90)ViewN/AView Earnings Details
3/9/2017Q4 2016($4.05)($1.65)$0.02 million$0.04 millionViewN/AView Earnings Details
11/3/2016Q316($0.75)($0.25)$0.07 million$0.22 millionViewN/AView Earnings Details
8/4/2016Q2 2016($1.95)($2.10)$0.04 million$0.09 millionViewN/AView Earnings Details
5/5/2016Q1 2016($2.40)$0.60$0.07 million$0.02 millionViewN/AView Earnings Details
3/10/2016Q415($0.85)($2.00)$0.07 million$0.08 millionViewListenView Earnings Details
11/5/2015Q315($0.80)($0.35)$0.06 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q215($0.80)($0.85)$0.09 million$0.14 millionViewN/AView Earnings Details
5/8/2015Q1 2015($0.80)($0.85)$0.05 million$0.19 millionViewN/AView Earnings Details
3/13/2015Q4 2014($0.80)($0.80)$0.06 million$0.06 millionViewN/AView Earnings Details
11/7/2014Q3 14($0.70)($0.85)$0.06 million$0.02 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.90)($0.40)$0.07 million$0.06 millionViewN/AView Earnings Details
5/19/2014Q114($0.75)($1.75)$0.05 million$0.05 millionViewN/AView Earnings Details
3/17/2014Q414($1.30)($0.70)$0.05 million$0.04 millionViewN/AView Earnings Details
11/14/2013Q3 2013($3.15)($7.20)$0.07 million$0.07 millionViewN/AView Earnings Details
5/15/2013Q1 2013($3.30)$0.03 millionViewN/AView Earnings Details
11/17/2011Q3 2011($22.50)($6.75)ViewN/AView Earnings Details
8/15/2011Q2 2011($119.25)ViewN/AView Earnings Details
5/18/2011Q1 2011($48.75)($71.65)ViewN/AView Earnings Details
11/18/2010Q3 2010($34.90)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Fibrocell (NASDAQ:FCSC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Fibrocell (NASDAQ FCSC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 37.32%
Insider Trading History for Fibrocell (NASDAQ:FCSC)
Institutional Ownership by Quarter for Fibrocell (NASDAQ:FCSC)

Fibrocell (NASDAQ FCSC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/11/2017Randal J KirkMajor ShareholderBuy2,727,273$0.77$2,100,000.21View SEC Filing  
12/2/2016David PernockChairmanBuy50,000$0.92$46,000.00105,600View SEC Filing  
11/13/2015David PernockCEOBuy3,000$5.00$15,000.0055,600View SEC Filing  
8/11/2015David PernockCEOBuy3,500$6.54$22,890.00View SEC Filing  
7/27/2015Randal J KirkMajor ShareholderBuy975,987$5.80$5,660,724.60View SEC Filing  
5/13/2015David PernockCEOBuy16,600$4.30$71,380.00View SEC Filing  
12/12/2014David PernockCEOBuy5,000$2.52$12,600.00View SEC Filing  
11/20/2014David PernockCEOBuy5,000$2.54$12,700.00View SEC Filing  
11/20/2014John Michael MaslowskiVPBuy1,000$2.54$2,540.00View SEC Filing  
6/5/2014Christine St.ClareDirectorBuy10,000$3.00$30,000.00View SEC Filing  
6/5/2014David PernockCEOBuy12,500$2.95$36,875.00View SEC Filing  
6/4/2014Kelvin MooreDirectorBuy4,557$2.99$13,625.43View SEC Filing  
6/4/2014Randal J KirkMajor ShareholderBuy400,000$2.90$1,160,000.00View SEC Filing  
1/24/2014Randal J KirkMajor ShareholderBuy1,024,590$4.88$4,999,999.20View SEC Filing  
11/21/2013David PernockCEOBuy10,000$3.69$36,900.00View SEC Filing  
11/20/2013Gregory L WeaverCFOBuy10,000$3.51$35,100.00View SEC Filing  
10/1/2013Randal J KirkMajor ShareholderBuy3,658,536$4.10$14,999,997.60View SEC Filing  
7/26/2013Randal J KirkMajor ShareholderBuy1,243,781$6.03$7,499,999.43View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Fibrocell (NASDAQ FCSC) News Headlines

Source:
DateHeadline
Fibrocell executes 1:5 reverse splitFibrocell executes 1:5 reverse split
seekingalpha.com - May 25 at 10:31 AM
Fibrocell Announces One-for-Five Reverse Stock SplitFibrocell Announces One-for-Five Reverse Stock Split
finance.yahoo.com - May 24 at 5:41 PM
Blog Exposure - Fibrocell Presented Update on Interim Results and Progress of its Phase-1/2 Clinical Trial of FCX-007 at International Investigative Dermatology MeetingBlog Exposure - Fibrocell Presented Update on Interim Results and Progress of its Phase-1/2 Clinical Trial of FCX-007 at International Investigative Dermatology Meeting
finance.yahoo.com - May 23 at 8:18 AM
Fibrocells gene therapy FCX-007 shows positive effect in RDEB study; shares up 4%Fibrocell's gene therapy FCX-007 shows positive effect in RDEB study; shares up 4%
seekingalpha.com - May 21 at 12:33 PM
Fibrocell Science (FCSC) Announces Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene TherapyFibrocell Science (FCSC) Announces Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy
www.streetinsider.com - May 21 at 8:15 AM
Form 8-K Fibrocell Science, Inc. For: May 21Form 8-K Fibrocell Science, Inc. For: May 21
www.streetinsider.com - May 21 at 8:15 AM
Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive ...Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive ...
www.globenewswire.com - May 21 at 8:15 AM
BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For ...BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For ...
www.reuters.com - May 21 at 8:15 AM
Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis BullosaFibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
finance.yahoo.com - May 21 at 8:15 AM
 Brokerages Anticipate Fibrocell (FCSC) Will Announce Earnings of -$0.11 Per Share Brokerages Anticipate Fibrocell (FCSC) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - May 20 at 9:28 PM
Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology MeetingFibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting
finance.yahoo.com - May 16 at 5:42 PM
Fibrocell (FCSC) Lifted to Buy at Zacks Investment ResearchFibrocell (FCSC) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - May 15 at 10:58 PM
Form 10-Q Fibrocell Science, Inc. For: Mar 31Form 10-Q Fibrocell Science, Inc. For: Mar 31
www.streetinsider.com - May 11 at 8:27 AM
Fibrocell (FCSC) Announces Quarterly  Earnings Results, Beats Estimates By $0.06 EPSFibrocell (FCSC) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - May 10 at 4:17 PM
Fibrocell (FCSC) Given a $6.00 Price Target by HC Wainwright AnalystsFibrocell (FCSC) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 10 at 1:28 PM
Fibrocell Reports First Quarter 2018 Financial Results and Recent HighlightsFibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
finance.yahoo.com - May 10 at 8:24 AM
Fibrocell (FCSC) Upgraded to "Sell" by ValuEngineFibrocell (FCSC) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - May 4 at 12:13 AM
 Brokerages Expect Fibrocell (FCSC) to Announce -$0.17 EPS Brokerages Expect Fibrocell (FCSC) to Announce -$0.17 EPS
www.americanbankingnews.com - May 3 at 6:52 PM
Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent HighlightsFibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights
finance.yahoo.com - May 3 at 8:17 AM
Fibrocell (FCSC) Scheduled to Post Quarterly Earnings on TuesdayFibrocell (FCSC) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:46 AM
Fibrocell (FCSC) Rating Increased to Buy at Zacks Investment ResearchFibrocell (FCSC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:28 AM
Form 8-K Fibrocell Science, Inc. For: Apr 18Form 8-K Fibrocell Science, Inc. For: Apr 18
www.streetinsider.com - April 18 at 5:45 PM
Health Care Sector Update for 04/18/2018: SLDB,FCSC,ABT,ENDP,EGRXHealth Care Sector Update for 04/18/2018: SLDB,FCSC,ABT,ENDP,EGRX
www.nasdaq.com - April 18 at 5:45 PM
BRIEF-Fibrocell Announces Review Of Strategic AlternativesBRIEF-Fibrocell Announces Review Of Strategic Alternatives
www.reuters.com - April 18 at 5:45 PM
Fibrocell Announces Review of Strategic AlternativesFibrocell Announces Review of Strategic Alternatives
globenewswire.com - April 18 at 8:16 AM
Fibrocell Science shares halted pending newsFibrocell Science shares halted pending news
seekingalpha.com - April 18 at 8:10 AM
Fibrocell (FCSC) Expected to Announce Earnings of -$0.17 Per ShareFibrocell (FCSC) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - April 16 at 9:21 AM
Fibrocell Science (FCSC) Lowered to "Sell" at ValuEngineFibrocell Science (FCSC) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - April 14 at 8:37 PM
Fibrocell Science (FCSC) Given a $6.00 Price Target at HC WainwrightFibrocell Science (FCSC) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 11 at 7:53 PM
Fibrocell Science (FCSC) Rating Lowered to Sell at Zacks Investment ResearchFibrocell Science (FCSC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 10 at 5:02 PM
Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USAFibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
finance.yahoo.com - April 10 at 8:27 AM
Fibrocell Science (FCSC) Cut to Strong Sell at ValuEngineFibrocell Science (FCSC) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM
Fibrocell Science (FCSC) Receives "Buy" Rating from Griffin SecuritiesFibrocell Science (FCSC) Receives "Buy" Rating from Griffin Securities
www.americanbankingnews.com - April 6 at 9:10 AM
Zacks: Analysts Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.22 Per ShareZacks: Analysts Anticipate Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - March 30 at 1:20 PM
Reviewing OptiNose (OPTN) & Fibrocell Science (FCSC)Reviewing OptiNose (OPTN) & Fibrocell Science (FCSC)
www.americanbankingnews.com - March 30 at 9:38 AM
Fibrocell Science (FCSC) PT Set at $6.00 by HC WainwrightFibrocell Science (FCSC) PT Set at $6.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 2:06 PM
Zacks Investment Research Lowers Fibrocell Science (FCSC) to HoldZacks Investment Research Lowers Fibrocell Science (FCSC) to Hold
www.americanbankingnews.com - March 24 at 12:28 AM
Fibrocell Sciences (FCSC) CEO John Maslowski on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaFibrocell Science's (FCSC) CEO John Maslowski on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 20 at 8:28 AM
Fibrocell Science (FCSC) Releases  Earnings Results, Beats Estimates By $0.38 EPSFibrocell Science (FCSC) Releases Earnings Results, Beats Estimates By $0.38 EPS
www.americanbankingnews.com - March 19 at 1:48 PM
HC Wainwright Analysts Give Fibrocell Science (FCSC) a $6.00 Price TargetHC Wainwright Analysts Give Fibrocell Science (FCSC) a $6.00 Price Target
www.americanbankingnews.com - March 19 at 1:03 PM
Earnings Scheduled For March 19, 2018 - BenzingaEarnings Scheduled For March 19, 2018 - Benzinga
www.benzinga.com - March 19 at 8:22 AM
Does Fibrocell Science Inc’s (NASDAQ:FCSC) Past Performance Indicate A Stronger Future?Does Fibrocell Science Inc’s (NASDAQ:FCSC) Past Performance Indicate A Stronger Future?
finance.yahoo.com - March 19 at 8:22 AM
Fibrocell Reports 2017 Financial Results and Recent HighlightsFibrocell Reports 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 19 at 8:22 AM
Pre-Market Earnings Report for March 19, 2018 : CSIQ, MDWD, LEJU, FCSC - NasdaqPre-Market Earnings Report for March 19, 2018 : CSIQ, MDWD, LEJU, FCSC - Nasdaq
www.nasdaq.com - March 17 at 8:26 AM
Fibrocell Science Inc (FCSC) Sees Large Decrease in Short InterestFibrocell Science Inc (FCSC) Sees Large Decrease in Short Interest
www.americanbankingnews.com - March 14 at 1:38 AM
Fibrocell Science (FCSC) Rating Increased to Buy at Zacks Investment ResearchFibrocell Science (FCSC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:52 PM
Zacks: Brokerages Expect Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per ShareZacks: Brokerages Expect Fibrocell Science Inc (FCSC) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - March 13 at 12:03 PM
Fibrocell Science (FCSC) Set to Announce Quarterly Earnings on MondayFibrocell Science (FCSC) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 13 at 10:56 AM
Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - GlobeNewswire (press release)Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM
Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - NasdaqFibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and ... - Nasdaq
www.nasdaq.com - March 12 at 9:02 AM

SEC Filings

Fibrocell (NASDAQ:FCSC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Fibrocell (NASDAQ:FCSC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Fibrocell (NASDAQ FCSC) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.